Clinical Trial Update: SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SU011248 to Interferon alfa as first-line therapy for metastatic renal cell carcinoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• SU011248

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2009-12-10